Clinical trial · Observational
Cell Free DNA in Mature B-cell Lymphoma
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
NCT04088422CI-TRIAL-00064245recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mature B-Cell Lymphoma | Mature B-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| peripheral blood collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- B-cell lymphoma
- interventionNames
- Procedure: peripheral blood collection
Primary outcomes (1)
- measure
- progression free survival
- timeFrame
- 2-year
Secondary outcomes (2)
- measure
- overall survival
- timeFrame
- 2-year
- measure
- Complete Response rate
- timeFrame
- 6 weeks after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * 18 years or older Exclusion Criteria: * Chemotherapy before * Other tumors
References
Publications (0)
Data not yet available
No reference posted for this study.